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Summary
Members of the T-box family of proteins play a fundamental role in patterning the developing
vertebrate heart; however, the precise cellular requirements for any one family member and the
mechanism by which individual T-box genes function remains largely unknown. In this study, we
have investigated the cellular and molecular relationship between two T-box genes, Tbx5 and
Tbx20. We demonstrate that blocking Tbx5 or Tbx20 produces phenotypes that display a high degree
of similarity, as judged by overall gross morphology, molecular marker analysis and cardiac
physiology, implying that the two genes are required for and have non-redundant functions in early
heart development. In addition, we demonstrate that although co-expressed, Tbx5 and Tbx20 are not
dependent on the expression of one another, but rather have a synergistic role during early heart
development. Consistent with this proposal, we show that TBX5 and TBX20 can physically interact
and map the interaction domains, and we show a cellular interaction for the two proteins in cardiac
development, thus providing the first evidence for direct interaction between members of the T-box
gene family.
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Introduction
The vertebrate heart constitutes the earliest functional organ in the developing embryo and
about 1% of all live births exhibit congenital heart disease (Hoffman, 1995a; Hoffman,
1995b; Payne et al., 1995). It is becoming increasingly clear that a complex molecular
regulatory network is required to initiate and complete the formation of a functional heart. The
proteins implicated in this process include a number of transcription factors from a range of
transcription factor families, including the T-box, basic helix-loop-helix homeodomain, zinc
finger and MADS domain families (Cripps and Olson, 2002; Harvey, 2002; Zaffran and Frasch,
2002).
The T-box family of transcription factors is a large family of proteins involved in determining
early cell fate decisions and controlling differentiation and organogenesis. Two sets of clinical
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data have provided direct evidence for the involvement of T-box genes in human heart
development (Packham and Brook, 2003; Ryan and Chin, 2003). Deletions of Tbx1 have been
found in individuals with DiGeorge syndrome (Baldini, 2004; Chieffo et al., 1997; Yagi et al.,
2003), and mutations in Tbx5 are associated with Holt-Oram Syndrome (HOS), a congenital
heart disease characterized by defects in heart formation and upper limb development (Basson
et al., 1997; Li et al., 1997). Clinical studies of individuals with HOS have demonstrated a
fundamental role for Tbx5 in heart development. HOS is a highly penetrant autosomal dominant
condition associated with skeletal and cardiac malformations (Newbury-Ecob et al., 1996).
Individuals with HOS often carry mutations within the coding region of the T-box transcription
factor Tbx5 (Basson et al., 1997; Basson et al., 1999; Benson et al., 1996; Li et al., 1997). The
role of Tbx5 in heart development, and in the HOS disease state, is further supported by recent
gene-targeting experiments in mouse. These studies demonstrate that mice heterozygous for
mutations in Tbx5 display many of the phenotypic abnormalities of individuals with HOS
(Bruneau et al., 2001) and show that TBX5 is required for growth and differentiation of the
left ventricle and atria as well as for proper development of the cardiac conduction system
(Moskowitz et al., 2004). Similar defects are seen in the zebrafish tbx5 mutant heartstrings,
suggesting that the expression and function of TBX5 is conserved throughout vertebrate
evolution (Garrity et al., 2002).
Previously, we have described the cloning and expression of the Xenopus laevis (X. laevis)
Tbx20 ortholog, Tbx20 (Brown et al., 2003). Studies of Tbx20 have demonstrated that, along
with Tbx5, Tbx20 is one of the first genes expressed in the vertebrate cardiac lineage. Moreover,
Tbx20 is expressed at the same time and in many of the same regions of the heart that also
express the heart markers Tbx5, Nkx2-5 and Gata4 (Horb and Thomsen, 1999; Laverriere et
al., 1994; Tonissen et al., 1994).
Despite our knowledge of the expression pattern of Tbx20, little is known of Tbx20 function
in heart development. In the zebrafish, it has recently been observed that eliminating
endogenous TBX20 (HrT) via morpholinos leads to cardiac defects (Szeto et al., 2002).
Specifically, TBX20 knockdown in zebrafish leads to dysmorphic hearts and a loss of blood
circulation. The morphological defects are not apparent until the cardiac looping stage, despite
high levels of Tbx20 during the earlier stages of specification and development, suggesting
that other T-box genes may act redundantly with Tbx20 during early heart development.
In this study we investigate the cellular and molecular relationship between Tbx5 and Tbx20
in X. laevis. We show that the phenotypes of knocking down TBX5 and TBX20 are highly
similar, with embryos derived from either Tbx5 or Tbx20 morpholino injections displaying
profound morphological defects, including pericardial edema, reduced cardiac mass and loss
of circulation. In addition, we show that the morphological phenotype is not a reflection of
alterations in the specification, commitment or differentiation of cardiac tissue. Thus, in
addition to sharing a number of molecular properties, we show that Tbx5 and Tbx20 function
in a non-redundant fashion and are essential for cardiac morphogenesis. However, despite the
similarities in phenotype and shared molecular properties, Tbx5 and Tbx20 also have
independent roles in heart development.
Given the similarity in TBX5 and TBX20 morphant phenotypes, we investigated the pathways
by which Tbx5 and Tbx20 function. We show that TBX5 and TBX20 do not function in a linear
pathway (i.e. Tbx20 does not act downstream of Tbx5, and vice versa), but rather imply a
synergistic role for these two proteins during early heart development. Consistent with this
proposal, we show that TBX5 and TBX20 can physically interact, map the interaction domains,
and show an interaction for the two proteins in cardiac development, therefore providing the
first evidence for interaction between members of the T-box gene family.
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XANF was generously provided by Paul Krieg (pXANF) (Small and Krieg, 2000) and the
cardiac troponin I (pXTnIc) plasmid was generously provided by Tim Mohun (Logan and
Mohun, 1993). Nkx2-5 was cloned by degenerate PCR from a ventral-anterior X. laevis cDNA
library (generous gift of Tim Mohun). Sequence analysis revealed that the clone shows
extensive homology to a partial sequence of the second X. laevis allele of Nkx2-5 (Accession
Number, AF283102). The clone is predicted to be full length and in vitro translation of the
protein gave a band of the correct size. The clone is referred to as pCRNkx-2.5B (Accession
Number, AY644403). To construct the pBS-Nkx2-5 hybridization probe, Nkx2-5 was
subcloned into pBLUESCRIPT II KS+. All other plasmids and construction information
available on request.
Transient transfections
293T cells were plated at 1×106 cells/well in six-well tissue culture plates 24 hours prior to
transfection. Plasmids used in transients are: the Nppa promoter-luciferase reporter (Bruneau
et al., 2001; Hiroi et al., 2001), pTbx5-V5, pTbx20-V5, pCMV-LacZ and pBS/KS. The amount
of luciferase reporter plasmid DNA was kept constant at 100 ng for Tbx5, while titering in
Tbx20 (25–100 ng). Expression vector plasmid DNA was kept constant at 100 ng total and 50
ng of lacZ reporter plasmid was used. Total amount of DNA was kept constant at 2 μg and
transfected using Lipofectamine 2000 (Invitrogen). Plasmid DNA was diluted in OPTI-MEM
(GibcoBRL) and complexes were allowed to form for 25 minutes at room temperature and
added to each well. Forty-eight hours post-transfection, cells were harvested using M-PER
(Pierce) with gentle shaking. Luciferase activity was normalized to β-galactosidase activity.
All assays were carried out three independent times in triplicate. Results were plotted using
normalized Relative Luciferase Units (RLUs).
Nuclear localization
NIH/3T3 cells were seeded in chamber slides at 6×103 cells/chamber 24 hours prior to
transfection. Cells were transfected with 187.5 ng pTbx20-V5 or pTbx5-V5 per chamber using
1.25 μl Polyfect (QIAgen) transfection reagent according to manufacturer’s protocol. At 48
hours, cells were washed twice with PBS and fixed in MEMFA for 1 hour (2 ml 10×MEM, 2
ml formaldehyde, 16 ml H2O) at 4°C. Cells were washed twice with PBST (PBS + 0.1%
Triton), blocked in PBST + 10% fetal bovine serum for 1 hour at 4°C, incubated at 4°C
overnight with anti-V5 (Invitrogen) diluted 1:1000 in PBST+Serum. Cells were washed three
times, blocked for 1 hour, then incubated for 1 hour at room temperature with goat anti-mouse
Cy2 (Jackson ImmunoResearch) diluted 1:200 in PBST+Serum. This process was repeated
using anti-phosphotyrosine (Upstate Biotechnology) as primary antibody to visualize the
cytoplasmic compartment and goat anti-mouse Cy3 (Jackson ImmunoResearch) secondary
antibody. Cells were washed three times, coverslipped and analyzed by confocal microscopy
on a Zeiss LSM 410.
Embryo injections
Preparation and injection of X. laevis embryos was carried out as previously described (Wilson
and Hemmati-Brivanlou, 1995). Embryos were staged according to Nieuwkoop and Faber
(Nieuwkoop and Faber, 1967). Two antisense morpholino oligonucleotides each were designed
against the Tbx5 and Tbx20 5′UTRs and start sites. Morpholinos were obtained from Gene
Tools, LLC. with the following sequences: Tbx20-MO1, 5′AAT CCA CTT CCA AGG GCA
GTT GCT T 3′; Tbx20-MO2, 5′GTT TGG GAG AAG GAG TGT ATT CCA T 3′; Tbx5-MO1,
5′TTA GGA AAG TGT CTC TGG TGT TGC C 3′; Tbx5-MO2, 5′CAT AAG CCT CCT CTG
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TGT CCG CCA T 3′; and control MO, 5′CCT CTT ACC TCA GTT ACA ATT TAT A 3′. The
human β-globin splice-mutant standard control morpholino from Gene Tools was used as
control. Equal amounts of both Tbx5 morpholinos were used in all injections. This combination
is referred to in the text and figures as ‘TBX5MO’. Tbx20 morpholinos were also injected in
combination, and referred to as ‘TBX20MO’. TBX5MO was injected at the optimal (40 ng)
or suboptimal (20 ng) doses, and TBX20MO was injected at the optimal (80 ng) or suboptimal
(40 ng) doses. ‘Optimal dose’ is defined as the dose empirically found to be efficient at blocking
protein translation both in vitro and in vivo, and inducing a cardiac phenotype in nearly 100%
of injected embryos, while ‘suboptimal dose’ refers to the dose empirically found to be below
the threshold of the full cardiac phenotype-inducing dose.
Whole-mount RNA in situ hybridization
Whole-mount in situ hybridization was performed as previously described (Harland, 1991).
Embryos were cleared using 2:1 benzyl benzoate/benzyl alcohol (Sigma) (Figs 5 and 9).
Immunohistochemistry
Embryos were collected and fixed for 2 hours at 4°C in 4% paraformaldehyde and rinsed in
PBS, incubated overnight in 30% sucrose in PBS at 4°C, mounted in OCT cryosectioning
medium (Tissue Tek) and snap frozen. Cryostat sections (14 μm) sections were rinsed with
wash buffer (PBS, 1% Triton, 1% serum), incubated at 4°C overnight with anti-tropomyosin
(1:50; Developmental Studies Hybridoma Bank) (Kolker et al., 2000), and phalloidin
conjugated to Alexa 488 flourophore (Molecular Probes). Sections were then rinsed with wash
buffer and incubated with anti-mouse Cy3-conjugated secondary antibody (1:200; Sigma).
Sections were rinsed and incubated for 20 minutes at room temperature with DAPI, cover
slipped and visualized on a Zeiss LSM410 confocal microscope.
Translation inhibition by morpholinos
In vitro translations were performed using TNT Coupled Reticulocyte Lysate System
(Promega) following the manufacturer’s protocol. We have recently demonstrated that X.
laevis SHP-2 is uniformly expressed throughout early development (Y. Langdon and F.L.C.,
unpublished) and anti-PTP1D/SHP2 primary antibody was used at 1:2500 (Transduction
Laboratories) as a loading control with peroxidase-conjugated AffiniPure donkey anti-mouse
(H+L) 2° antibody (1:10,000). V5-tagged proteins were probed with anti-V5 primary antibody
(Invitrogen) at 1:5000 dilution, and peroxidase-conjugated AffiniPure Donkey anti-mouse (H
+L) secondary antibody (Jackson ImmunoResearch Laboratories) at 1:10,000 dilution. For in
vivo translation analyses, embryos were injected with MOs and mRNA at the one-cell stage
and animal caps cut at stage 8. At sibling stage 10, 10 animal caps per treatment were collected
and lysed in 100 μl of lysis buffer: 200 mM NaCl, 20 mM NaF, 50 mM Tris (pH 7.5), 5 mM
EDTA, 1% IGEPAL, 1% Triton X-100 (Sigma), Complete EDTA-free Protease Inhibitor
(Roche). Lysates were resolved on 12% SDS-PAGE gels, and visualization was carried out
using Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences).
Glutathione-S-transferase pull-down assays
GST pull-down assays were performed using the MicroSpin GST Purification Module
(Amersham Biosciences) according to the manufacturer’s protocol. GST constructs were
transformed into BL21-Gold (DE3) cells (Stratagene) for protein induction. Transformed cells
were grown at 37°C to ODA600=0.8 and GST proteins were induced for 1.5 hours at 20–27°C
with 1 mM IPTG (Amersham Biosciences). Hemagglutinin (HA)-tagged putative interacting
proteins were produced in 293T cells. Lysates were sonicated three times for 10 seconds prior
to centrifugation at 16,000 g at 4°C for 10 minutes, and the supernatant was collected. GST-
fusion protein lysates and putative interacting protein lysates were loaded on GST columns,
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incubated for 1.5 hours at 25°C, eluted, electrophoresed on a 12% SDS-PAGE gel and
transferred to PolyScreen PVDF Transfer Membranes. HA-tagged proteins were detected with
mouse HA.11 primary antibody (1:1,000, Covance Research Products) and with peroxidase-
conjugated AffiniPure donkey anti-mouse (H+L) secondary antibody (1:10,000, Jackson
ImmunoResearch Laboratories). GST-fusion proteins were detected with rabbit anti-GST
primary antibody (1:25,000, Sigma-Aldrich) and with peroxidase-conjugated AffiniPure
donkey anti-rabbit (H+L) secondary antibody (1:10,000, Jackson ImmunoResearch
Laboratories).
Results
TBX5 and TBX20 are required for heart morphogenesis
To analyze the requirement for Tbx5 and Tbx20 in cardiogenesis, antisense morpholinos were
designed against the 5′UTRs and translational start sites of the respective cDNAs (Fig. 1A)
(Heasman et al., 2000). Owing to the lack of antibodies against endogenous TBX5 or TBX20,
we tested the efficiency and specificity of morpholino translation inhibition using V5 epitope-
tagged versions of TBX5 and TBX20 both in vitro and in vivo. To this end, transcription/
translation reactions were incubated with each cDNA construct alone and together with
increasing concentrations of morpholinos (Fig. 1B,C). TBX20MO was included as control for
TBX5MO and vice versa, and a ControlMO used for both. Results from these assays show that
TBX5MO blocks translation of TBX5-V5 while TBX20MO and ControlMO do not. Similarly,
TBX20MO blocks translation of TBX20-V5 in vitro (Fig. 1B,C).
To determine if TBX5MO and TBX20MO block translation in vivo, we injected Tbx5-V5 or
Tbx20-V5 mRNA alone or in the presence of morpholinos into one-cell stage embryos. Animal
caps were cut at stage 8 and allowed to develop to stage 10, at which point western blot analyses
were performed. Results from these studies demonstrate that in animal caps, TBX5MO blocks
TBX5-V5 translation, while TBX20MO blocks TBX20-V5 translation (Fig. 1D,E). We have
further shown via sequence alignments that Tbx5 does not contain binding sites for the
Tbx20 morpholinos and vice versa (see Fig. S1 in the supplementary material). We did note
that the introduction of TBX20MO results in a slight decrease in TBX5 in vivo, and vice versa
(see Discussion).
To determine the requirement of TBX5 and TBX20 in heart development, we injected
TBX5MO, TBX20MO, or ControlMO into one-cell stage embryos. No significant differences
are seen between TBX5 morphants, TBX20 morphants, control morphants, or uninjected
siblings throughout gastrulation and neurulation stages. However, a slight delay in
developmental stage is evident in TBX5 and TBX20 morphants relative to control morphants
and uninjected embryos by neurulation stages (~stage 16). By cardiac looping stages (~stage
38) (Kolker et al., 2000; Mohun and Leong, 1999; Mohun, 2000; Newman and Krieg, 1999),
a reduction in cardiac mass is evident in the morphants, and by stage 38 both morphants display
grossly abnormal heart morphology (Fig. 2A–F). At this stage, 82% of TBX5 morphants and
100% of TBX20 morphants display prominent cardiac defects, as scored by the presence of an
unlooped heart tube, a reduction in cardiac mass and the presence of a pericardial edema (Fig.
2G). After terminal cardiomyocyte differentiation has begun (~stage 45) (Kolker et al., 2000;
Mohun and Leong, 1999; Mohun et al., 2000; Newman and Krieg, 1999), TBX5 and TBX20
morphants display dramatically smaller hearts and in many embryos cardiac tissue is barely
detectable (Fig. 2E,F). However, the remaining cardiac tissue still retains some degree of
contractility, although it is confined to a small patch of contractile tissue in the dorsal-most
aspect of the cardiac cavity. Both TBX5 and TBX20 morphants also display abnormal eyes,
which is consistent with studies showing the involvement of both genes in eye development
(Fig. 2) (Carson et al., 2004; Koshiba-Takeuchi et al., 2000; Leconte et al., 2004). Embryos
derived from injection of Tbx20 morpholinos directed against the antisense transcript, Tbx5
Brown et al. Page 5













morpholinos containing mismatches, MOs directed against zebrafish Tbx5 and Gene Tools
LLC’s MO control, produced no observable phenotype at any concentration (data not shown).
These observations, and the findings that the TBX5 and TBX20 protein levels can be reduced
or eliminated both in vitro and in vivo, suggest that the phenotypes we observe are specific for
knocking down TBX5 and TBX20.
To further define the requirements for Tbx5 and Tbx20 during cardiogenesis, we carried out a
detailed analysis of TBX5MO-and TBX20MO-derived hearts relative to those from
ControlMO injections. For these analyses, staged-matched TBX5MO, TBX20MO and
ControlMO embryos were collected at stage 37, serial sectioned and stained for the terminal
differentiation markers tropomyosin and cardiac actin, and counterstained with DAPI (Fig. 3).
Results from this analysis clearly demonstrate that TBX5MO- and TBX20MO-derived hearts
fail to undergo cardiac looping and chamber formation. In addition, quantification of total
cardiac cell number by serial sectioning shows that both TBX5MO and TBX20MO hearts have
a significant reduction in cell number compared with controls, and TBX20MO-derived hearts
have significantly fewer cardiomyocytes than those from TBX5MO (Fig. 3M).
In addition to these defects, we note some features unique to both the TBX5MO- and
TBX20MO-derived hearts, most notably TBX5MO hearts remain as an open cardiac trough
(Mohun et al., 2000) throughout development and fail to form a cardiac tube (Fig. 3E–H). By
contrast, TBX20MO-derived embryos form a cardiac tube; however, the lumen often collapses.
We also note a decrease in cardiac actin in TBX20MO-derived hearts (Fig. 3L) compared with
TBX5MO or control hearts (Fig. 3D,H). Together, these data demonstrate a requirement for
both Tbx5 and Tbx20 in normal heart morphogenesis, and imply that TBX5 cannot compensate
for the loss of TBX20 nor can TBX20 compensate for the loss of TBX5. They also suggest
that Tbx5 and Tbx20 play non-redundant roles during normal heart development.
Analysis of hearts derived from TBX5MO and TBX20MO embryos shows a significant
decrease in cardiac cell number. To determine if this is due to alterations in cardiac cell
commitment, we performed whole-mount in situ hybridization with the early heart marker,
Nkx2.5 (Fig. 4). This analysis was carried out on staged-matched embryos derived from
TBX5MO, TBX20MO and ControlMO embryos over the period of cardiac cell commitment,
migration and differentiation (stages 16–36). We could not detect any obvious difference in
the number or spatial distribution of Nkx2.5-expressing cells prior to stage 24 (Fig. 4).
Consistent with our initial analysis, after stage 24, the hearts from TBX5MO and TBX20MO
embryos are morphologically abnormal and smaller in size, and therefore show a reduced
domain of Nkx2.5 expression.
The above results demonstrate that Tbx5 and Tbx20 are required for normal heart
morphogenesis, but not for specification and migration of the cardiac precursors. To extend
these findings, in situ hybridization was performed on stage 36 morphants and controls using
the late heart markers atrial natriuretic factor (XANF) (Small and Krieg, 2000) and cardiac
troponin I (XTnIc) (Drysdale et al., 1994). As shown in Fig. 5, the terminally differentiated
cardiomyocyte marker XTnIc displays properly localized expression in the cardiac tissue of
morphant embryos and appears to be expressed to the same degree, although owing to the
reduced cardiac mass, it is expressed in fewer cells (Fig. 5D–F). XANF is a putative target of
Tbx5, and its expression is reduced in the absence of Tbx5 in mice (Bruneau et al., 2001). In
agreement with these findings, we show that Xenopus TBX5 activates transcription of a rat
Nppa/ANF reporter plasmid (Fig. 6) and, consistent with TBX5MO blocking TBX5, XANF
expression is either greatly reduced or absent in TBX5 morphants; however, XANF is still
detected in TBX20 morphants (Fig. 5A–C). These results indicate that terminal differentiation
still occurs in both TBX5 and TBX20 morphant embryos and implies that XANF is an
evolutionarily conserved target of TBX5.
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Tbx5 and Tbx20 are not dependent on the expression of one another
As Tbx5 and Tbx20 are co-expressed within the heart and have similar requirements in heart
development, we next asked whether Tbx5 and Tbx20 function linearly within the same
molecular pathway. To address this question, we analyzed the expression of Tbx20 in
TBX5MO-injected embryos and Tbx5 expression in TBX20MO-injected embryos. We could
detect no differences in the expression of either gene in morpholino-injected embryos (Fig. 7);
both genes remain expressed in the forming heart tissue, despite the reduction of cardiac tissue
mass in morpholino-injected embryos. Based on these results, we conclude TBX5 is not
essential for Tbx20 expression, nor is Tbx20 dependent on TBX5.
TBX20 affects TBX5 transcriptional activity
Our results strongly suggest that Tbx5 and Tbx20 do not function linearly within the same
pathway, yet have a similar requirement in heart development. We therefore carried out a series
of experiments to test if TBX5 and TBX20 have either competing or complimentary functions
at the molecular level. We first tested the cellular localization of TBX5 and TBX20. For these
studies, V5 epitope-tagged versions of the full-length cDNAs were transfected into NIH/3T3
cells. Immunohistochemistry on the transfected cells show that similar to TBX5 (Collavoli et
al., 2003; Fan et al., 2003; Zaragoza et al., 2004), TBX20 is localized exclusively to the nucleus
(Fig. 6C–H).
We next tested whether TBX5 and TBX20 can function to regulate the levels of transcription
of the TBX5 target gene Nppa/ANF. To test for DNA-specific binding and transcriptional
activities, we transfected in full-length versions of Tbx5 and Tbx20, either alone or in
combination, with the putative Tbx5 target Nppa/ANF reporter construct into 293T cells.
Consistent with studies using the mouse Tbx5 ortholog (Bruneau et al., 2001; Hiroi et al.,
2001), TBX5 can weakly activate the rat Nppa/ANF reporter. By contrast, Tbx20 alone can
activate Nppa/ANF in a dose dependent fashion. However, in the presence of TBX5, TBX20
can have the converse effect on the Nppa/ANF reporter. In the presence of TBX5, at high and
low doses of TBX20 there is increased activation of the reporter construct, while at moderate
doses there is a repressive effect (Fig. 6I). Thus, the presence of TBX5 appears to alter TBX20
transcriptional activity.
TBX5 and TBX20 physically interact with one another
Given the similarity in phenotypes of TBX5 and TBX20 morphant embryos, and the
observation that Tbx5 and Tbx20 are not dependent on the expression of one another, we next
assessed whether TBX5 and TBX20 can physically interact. TBX5 fused to Glutathione-S-
Transferase (GST) was incubated with HA-tagged TBX20 or NKX2-5. Pull-down experiments
were then performed to assess whether TBX20 can bind to TBX5. NKX2-5 has been shown
to interact with TBX5 and thus serves as a positive control (Bruneau et al., 2001; Hiroi et al.,
2001). As shown in Fig. 8A, bacterially translated GST-TBX5 is able to bind HA-TBX20 and
HA-NKX2-5 produced from 293T cells, in contrast to GST alone, which does not bind either
protein. These results reveal that TBX5 and TBX20 can interact in vitro. This is the first report
of physical interaction between T-box proteins.
Having demonstrated that TBX5 and TBX20 interact, we next mapped the interaction domains
of TBX5 and TBX20. To this end, we constructed a deletion series of both GST-tagged TBX5
and HA-tagged TBX20. As shown in Fig. 8C, GST-TBX5 proteins lacking the C terminus still
bind HA-TBX20; however, when the small N terminus and T-box domain are removed from
GST-TBX5, HA-TBX20 fails to bind. Thus, the domain responsible for TBX20 binding lies
within the N-terminus and T-domain of TBX5. Similarly, a C-terminal deletion of HA-TBX20
still binds to GST-TBX5, in contrast to deletions of the HA-TBX20 N-terminus and T-domain
(Fig. 8E). As seen in the ΔN/C lane in Fig. 8E, the HA-TBX20 deletion containing only the
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T-box domain did not bind GST-TBX5. However, we were unable to obtain comparable
amounts of the HA-T20-ΔN/C protein, as seen in the input lane. This could be due to mRNA
or protein instability. In an attempt to circumvent this problem, the amount of HA-T20-ΔN/C
protein incubated with GST-TBX5 was increased twofold compared with the rest of the
experiments. These results indicate that the N terminus and possibly the T-domain of TBX20
are required for its interaction with TBX5, although we cannot rule out the possibility that the
amount of HA-T20-ΔN/C protein was insufficient to identify a requirement for the T-domain.
In summary, our results reveal that the domains responsible for the interaction between TBX20
and TBX5 map to within the N-terminal and T-box domains in both proteins.
Tbx5 and Tbx20 cooperate to regulate heart morphogenesis
Given that TBX5 and TBX20 physically interact with one another, we hypothesized that
Tbx5 and Tbx20 may function cooperatively to control cardiogenesis. To test this hypothesis,
we co-injected concentrations of TBX5MO and TBX20MO below the threshold at which
cardiac phenotypes are efficiently induced when injected individually. At a concentration of
40 ng per embryo for Tbx5 morpholinos and 80 ng per embryo for Tbx20 morpholinos,
injections yield consistent heart phenotypes in 82% of TBX5MO-injected embryos and in
100% of TBX20MO-injected embryos (Fig. 2). We refer to this dose as the ‘optimal’ dose,
because it is the dose that efficiently blocks translation of Tbx5 and Tbx20 in vivo (Fig. 1D,E)
and the dose that gives efficient and penetrant cardiac phenotypes. At half doses, 20 ng per
embryo for TBX5MO and 40 ng per embryo for TBX20MO, each morpholino yields
significantly fewer and weaker heart phenotypes compared with the full dose (Fig. 9M, data
not shown). We refer to this concentration as the ‘suboptimal’ dose for inducing cardiac defects.
The terms ‘optimal’ and ‘suboptimal’ are only used to refer to the concentrations that yield
fully penetrant or partially penetrant cardiac phenotypes, respectively.
To address the question of whether Tbx5 and Tbx20 cooperate in cardiogenesis, we injected
TBX5MO and TBX20MO individually at suboptimal doses in combination with ControlMO
to keep total morpholino concentrations equal in all injections. TBX5MO was then co-injected
with TBX20MO, each at the suboptimal dose. ControlMO injected at 80 ng/embryo served as
control. As shown in Fig. 9, only 4% of embryos injected with suboptimal TBX5MO/
ControlMO displayed a pericardial edema, unlooped heart tubes and a reduction in cardiac
mass. Suboptimal TBX20MO/ControlMO yields only 13% cardiac defects. In suboptimal
injections, the majority of embryos appeared normal, while the few cardiac phenotypes
produced were much less severe than at optimal doses (e.g. barely detectable reduction in
cardiac mass, slight perturbation of looping and little or no pericardial edema). When co-
injected at suboptimal doses, 74% of TBX5MO/TBX20MO co-injected embryos display
dramatic cardiac defects compared with 0% of ControlMO-injected embryos (Fig. 9A–L). The
observation that the percentage of heart defects in double morphants is more than additive
suggests that Tbx5 and Tbx20 synergistically act to control heart morphogenesis.
If Tbx5 and Tbx20 cooperate to regulate cardiogenesis, one might expect a more severe
alteration in cardiac morphology and marker expression when the levels of both proteins are
reduced. To address this issue, we performed in situ hybridization on stage 36 embryos from
the above double injection experiment using Nkx2-5, XANF and XTnIc probes. As shown in
Fig. 9, all three markers are expressed normally in embryos injected with suboptimal doses of
TBX5MO and TBX20MO when compared with ControlMO. However, heart marker
expression in the double morphant embryos is markedly reduced, particularly XANF. Both
Nkx2-5 and XTnIc are still detectable in the heart region, albeit in fewer cells. Thus, the
synergistic cooperation of TBX5 and TBX20 are required for proper heart development.
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Members of the T-box family of proteins play a fundamental role in patterning the developing
vertebrate heart; however, the precise cellular requirements for any one family member remains
largely unknown. In this study, we demonstrate that TBX5 and TBX20 are both required for
early cardiac morphogenesis. Moreover, we show that TBX5 and TBX20 function in the same
pathway, implying a synergistic role for these two proteins during early heart development.
Consistent with this proposal, we show that TBX5 and TBX20 can physically and functionally
interact, therefore providing the first evidence for direct interaction between members of the
T-box gene family.
Functions of Tbx5 and Tbx20 in cardiac morphogenesis
Our studies show that Tbx5 and Tbx20 are required for similar cellular processes in the
developing heart. These data demonstrate a non-redundant function for TBX5 and TBX20
during cardiac morphogenesis; neither protein can compensate for the other in heart
morphogenesis. The lack of redundancy at the molecular level is corroborated by the
observation that the putative TBX5 target gene XANF either is not expressed or is expressed
very weakly in TBX5 morphant embryos, while being expressed at the proper time, place and
levels in TBX20 morphant embryos. Together, these data suggest that TBX5 and TBX20 act
in a non-redundant fashion to control morphogenetic movements of early heart tissue.
The cardiac defects, in response to a reduction of either TBX5 or TBX20, appear to represent
a block in an early morphological step in heart formation. As the spatial distribution of
Nkx2-5 is unaltered throughout early development in TBX5MO-, TBX20MO- and ControlMO-
injected embryos, and as Nkx2.5, Tbx5 and Tbx20 continue to be expressed until the later stages
of heart development, and TBX5 and TBX20 morphants express markers of terminal muscle
differentiation, neither Tbx5 nor Tbx20 appears to be required for commitment, migration or
terminal differentiation of cardiac tissue. Thus, both Tbx5 and Tbx20 appear to be required to
direct the coordinated events that occur during the early steps of heart morphogenesis.
Consistent with this hypothesis, both TBX5 and TBX20 morphant-derived hearts are greatly
extended along the anteroposterior axis, and the heart tube fails to correctly loop and undergo
chamber formation. As a result, embryos display pericardial edemas, have impaired blood flow
(see Figs S2 and S3 in the supplementary material), an irregular heartbeat (data not shown)
and ultimately die. Thus, the alteration in heart morphology appears to be the primary outcome
of perturbing TBX5 or TBX20 function.
Past attempts to interfere with Tbx5 function in X. laevis were carried out by the misexpression
of a putative interfering form of Tbx5 that leads to either the absence or severe malformations
of the heart (Horb and Thomsen, 1999). In instances in which the heart does form, there is a
reduction or block in myocardial tissue formation and a failure of the heart to undergo looping.
Our results with Tbx5-specific morpholinos show a less severe heart phenotype than those
reported with the dominant interfering Tbx5 but bear a close resemblance to those reported for
the zebrafish Tbx5 mutant, heartstrings (Garrity et al., 2002). This may be due to the dominant-
interfering form of Tbx5 used in the X. laevis studies interfering with the function of both
Tbx5 and Tbx20 or possibly other T-box family members expressed in the developing heart,
e.g. Tbx1 and Tbx2 (Chapman et al., 1996), as has been shown for other Engrailed fusions
(Horb and Thomsen, 1997). However, in the absence of a TBX5-specific antibody, we cannot
rule out the possibility that some residual TBX5 protein is present in morphant embryos leading
to a less severe phenotype in our studies.
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Tbx5 and Tbx20 are not dependent on the function of one another
The phenotypes of TBX5 and TBX20 morphant embryos do not appear to act in a linear
pathway as the spatial and temporal expression of Tbx5 appears unaltered in TBX20 morphants,
and vice versa. These findings are in agreement with studies showing normal expression of
Tbx20 in Tbx5 mutant mice (Bruneau et al., 2001) but in apparent conflict with a second study
reporting the downregulation of Tbx5 in zebrafish embryos injected with a Tbx20 morpholino
(Szeto et al., 2002). Although the zebrafish and X. laevis orthologs of Tbx20 share a very high
degree of identity at the protein level (86%), the differences between the two orthologs may
reflect a species difference as, for example, has been reported for the endodermal-inducing
activities of the T-box-containing gene Brachyury (Marcellini et al., 2003). Although no
alterations in Tbx5 or Tbx20 RNA levels were observed in morphant embryos, we did observe
a downregulation of TBX5 protein in response to Tbx20 morpholinos in vivo, and vice versa,
but not in vitro (Fig. 1), raising the interesting possibility that cross-regulation may be occurring
between TBX5 and TBX20 at the level of translation. As similar studies have not been
conducted in zebrafish, it is not possible at this time to know the mechanisms of crossregulation
or whether this is a conserved response to interfering with TBX5 or TBX20.
TBX5 and TBX20 heterodimerization
Although Tbx5 and Tbx20 are co-expressed and both function in early heart development, the
genes appear to be regulated through separate pathways. For example, Tbx20 but not Tbx5 can
be induced in response to BMP2 signaling (Plageman and Yutzey, 2004). Taken together with
our results demonstrating a physical interaction between TBX5 and TBX20, these data would
suggest that TBX5 and TBX20 function in parallel pathways that converge upon TBX5:TBX20
heterodimerization. This model is also supported by our results showing a functional
interaction between TBX5 and TBX20: embryos derived from injections of suboptimal doses
of Tbx5 and Tbx20 morpholinos have only minor effects on heart development in a small
proportion of the embryos. However, when injected in combination, 74% of all embryos
examined displayed grossly abnormal heart formation.
What are the possible cellular functions of TBX5 and TBX20 in heart development? Past
studies of T-box genes have shown a direct link between members of the T-box gene family
and cell adhesion. For example, embryos homozygous for mutations in Brachyury, the
founding member of the T-box gene family, show an inability of the mesoderm to migrate
properly along the extracellular matrix leading to an inability of the mesodermal germ layer to
complete the morphogenetic movements normally associated with gastrulation (reviewed by
Showell et al., 2004). We propose an analogous model for TBX5 and TBX20 function in
regulating cell polarity or adhesion events associated with heart morphogenesis. We propose
that TBX5 and TBX20 function to control polarity or adhesive properties of cardiac tissue once
the two heart fields merge along the anterior midline, and that target specificity is regulated
through TBX5 and TBX20 protein-protein interactions. In agreement with this proposal, we
have recently shown that alterations in cardiac cell numbers, survival and proliferation in
TBX5MO-derived embryos are a secondary consequence of disrupting TBX5 function (S.
Goetz and F.L.C., unpublished). This observation, taken together with our findings that cardiac
gene expression patterns are not disrupted in TBX5MO- or TBX20MO-derived embryos,
suggests that the primary role for TBX5 and TBX20 is to control cardiac cell polarity or
adhesion.
It is worth noting that neither TBX5 nor TBX20 have strong transcriptional activation or
repression activity by themselves (Fig. 6) (Bruneau et al., 2001;Hiroi et al., 2001;Plageman
and Yutzey, 2004;Stennard et al., 2003). Thus, transcriptional activity appears to be governed
by protein-protein interactions. Past studies have identified several other interacting partners
for both TBX5 and TBX20. For example, both TBX5 and TBX20 have been shown to interact
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with the homeobox-containing transcription factor NKX2-5 (Bruneau et al., 2001;Hiroi et al.,
2001;Stennard et al., 2003), consistent with clinical studies showing that HOS patients and
humans heterozygous for NKX2-5 display many of the same cardiac defects (Elliott et al.,
2003;Goldmuntz et al., 2001;Prall et al., 2002).
How might TBX5:TBX20 heterodimerization affect target choice? It is possible that the role
of TBX5:TBX20 dimerization is to sequester TBX5 and thereby block its interaction with other
proteins such as NKX2.5, thereby indirectly inhibiting the induction of cardiac specific genes
such as XANF. However, several lines of evidence argue against such a proposal. For example,
at low and high concentrations TBX20 can increase transcription of the Nppa/ANF reporter in
the presence of TBX5, while showing a repressive activity at intermediate concentrations,
suggesting that in certain contexts TBX20 can cooperate with TBX5 to activate transcription,
while antagonizing TBX5 activity in others. An alternative possibility is that TBX20 target
choice and ability to function as a transcriptional activator or repressor is governed by its choice
of interacting partners. Consistent with this hypothesis, Stennard et al. (Stennard et al., 2003)
have shown that NKX2.5, GATA4 and GATA5 interact with TBX20, and the interactions
occur through the same domain of TBX20 that we have shown interacts with TBX5, at least
in the cases of NKX2.5 and GATA4. Furthermore, the authors have demonstrated that TBX20
can repress synergistic activation of a connexin 40 reporter by NKX2.5 and GATA4, while
synergistically activating the same reporter with NKX2.5 and GATA5. Thus, TBX20 may be
able to function both as a transcriptional activator or repressor, and this decision is based on
its choice of protein partners. In addition, TBX5 and TBX20 have been shown to display
different binding affinities for different T-box-binding sites (Stennard et al., 2003). For
example, TBX20, unlike TBX5 can bind to the Brachyury target site while TBX5 has a higher
affinity than TBX20 for the T-box binding site in the Nppa/ANF promoter. Thus, downstream
target selection may be dictated by homodimerization versus heterodimerization. This is
supported by the recent findings that several genes involved in heart development are found
to contain multiple T-box binding sites (R. Schwartz, personal communication; F.L.C.,
unpublished). Our model suggests that TBX5 and TBX20 target selection and transcriptional
activity is based on partner choice in a specific tissue at a specific time. However, it still remains
to be established which protein interactions take place in the developing heart and in turn, what
governs the choice of partners for TBX5 or TBX20. These are presently areas under active
investigation.
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Tbx5 and Tbx20 morpholinos block translation of their respective target proteins. (A)
TBX5MO and TBX20MO positions relative to Tbx5 and Tbx20 cDNA. (B) Inhibition of
TBX5-V5 translation in vitro by TBX5MO. TBX20MO and ControlMO serve as controls.
Each reaction contains 1 μg of Tbx5-V5 circular plasmid along with the indicated amounts of
MO. (C) Inhibition of TBX20-V5 translation in vitro by TBX20MO. TBX5MO and
ControlMO serve as controls. Each reaction contains 1 μg of Tbx20-V5 circular plasmid along
with the indicated amounts of MO. (D) Inhibition of TBX5-V5 translation by TBX5MO in
animal caps. TBX20MO and ControlMO serve as controls. Probed with anti-V5 and re-probed
with anti-PTP1D/SHP2 as a loading control. Embryos injected with 2 ng mRNA and the
indicated amounts of MO. (E) Inhibition of TBX20-V5 translation by TBX20MO in animal
caps. TBX20MO and ControlMO serve as controls. Probed with anti-V5 and re-probed with
anti-PTP1D/SHP2 as a loading control. Embryos injected with 2 ng mRNA and the indicated
amounts of MO.
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Tbx5 and Tbx20 are required for proper cardiogenesis. (A–F) Morpholino-injected tadpoles at
the indicated stages. Control morphant embryos (A,D), TBX5 morphant embryos (B,E) and
TBX20 morphant embryos (C,F). Arrows indicate the heart region, arrowheads indicate the
eye. (G) Chart displaying the percentage of morphants surviving and displaying cardiac
abnormalities, as scored by the presence of an unlooped heart tube, a reduction in cardiac mass
and the presence of a pericardial edema.
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TBX5 and TBX20 morphants fail to undergo looping and chamber formation and display
reduced cardiac cell numbers. Cryosections of TBX5 and TBX20 morphant hearts taken at the
anterior (outflow), middle (ventricular) and posterior (atrial) regions. (A–D) ControlMO, (E–
H) TBX5MO and (I–L) TBX20MO. Sections stained for tropomyosin (red), DAPI (blue) and
cardiac actin (green). (D,H,L) Same sections as B, F and J stained with cardiac actin. In the
looped control heart, the middle ventricular section also contains the atrium. (M) Mean number
of cells per heart obtained by cell counts of heart tissue in serial sections derived from a
minimum of three embryos.
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Cardiac specification is unaltered in TBX5 and TBX20 morphants. Whole-mount in situ with
Nkx2.5 on stage matched (A,D,G,J) ControlMO-, (B,E,H,K) TBX5MO- or (C,F,I,L)
TBX20MO-derived embryos.
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TBX5 and TBX20 morphants display dramatic morphological defects. Whole-mount in situ
hybridization of cleared stage 36 embryos. (A–C) ANF whole-mount in situ hybridization. (D–
F) XTnIc whole-mount in situ hybridization. (A,D) ControlMO. (B,E) TBX5MO and (C,F)
TBX20MO.
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Tbx5 and Tbx20 are localized to the nucleus and can activate transcription on the Nppa/ANF
promoter. (A) Schematic depicting the amino acid positions of the T-box domains of Tbx5 and
Tbx20. (B) Schematic of Rat Nppa/ANF-luciferase reporter construct showing T-box-binding
site consensus sequences and their relative position within the promoter relative to translation
start site. (C–H) Transfected cells were stained with anti-V5 (C,F; Cy2, green) for TBX5-V5
and TBX20-V5, and with anti-phosphotyrosine (D,G; Cy3, red) to visualize cytoplasmic
compartment. Overlaid image of Cy2 and Cy3 staining (E,H). (I) Rat ANF-luciferase co-
transfected with a constant amount of Tbx5 (100 ng) and increasing amounts of Tbx20 (25, 50,
100 and 500 ng) in 293T cells, and the level of transcriptional activation is expressed as relative
luciferase units based on average of three independent experiments performed in triplicate.
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Tbx5 and Tbx20 are not required for the expression of each other. Embryos injected at the one-
cell stage with ControlMO, TBX5MO or TBX20MO. (A,C) Whole-mount in situ hybridization
showing Tbx5 expression. (B,D) Whole-mount in situ hybridization showing Tbx20
expression.
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TBX5 and TBX20 physically interact. Cell lysates containing GST- and/or HA-tagged proteins
were incubated on GST and eluted, and separated by SDS-PAGE. GST proteins were detected
using anti-GST antibodies and HA-tagged proteins were detected with anti-HA antibodies. (A)
Association of TBX5 with TBX20 is shown by pull-down of HA-TBX20 with GST-TBX5.
HA-NKX2-5 serves as positive control. Fifteen percent of output and 7.5% of input was probed.
(B,C) Pull-down of full-length HA-TBX20 with a GST-tagged TBX5 deletion series reveals
an interaction domain in the N terminus and T-box region of TBX5. Each reaction was probed
with anti-HA antibodies (B). Fifteen percent of output and 7.5% of input was probed. (D,E)
Pull-down of HA-TBX20 deletion series with full-length GST-TBX5 reveals an interaction
domain within the N-terminus and T-box of TBX20. Each reaction was probed with anti-HA
antibodies (D). Fifteen percent of output and 7.5% of input was probed, except in the case of
ΔN/C, in which the amount of protein probed was only 4% owing to the increase in total amount
of ΔN/C protein used in pull-down (see text).
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Tbx5 and Tbx20 synergistically act to regulate cardiac gene expression. (A–L) Embryos
injected with the indicated morpholinos at the one-cell stage. (A–D) Nkx2-5 whole-mount in
situ hybridization. (E–H) XANF whole-mount in situ hybridization. (I–L) XTnIc whole-mount
in situ hybridization. (A,E,I) ControlMO, (B,F,J) TBX5MO injected at suboptimal dose,
(C,G,K) TBX20MO injected at suboptimal dose, (D,H,L) TBX5MO and TBX20MO injected
in combination at suboptimal doses. All embryo were cleared to reveal heart expression. (M)
Statistics for embryos injected with suboptimal doses of TBX5MO and TBX20MO in
combination with each other or with ControlMO. Hearts were judged as having defects if they
displayed a pericardial edema, an unlooped heart tube or reduction in cardiac mass.
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